Clinical Research Directory
Browse clinical research sites, groups, and studies.
Neoadjuvant Chemotherapy for Pancreatic Cancer Followed by GS and GnP
Sponsor: Kochi University
Summary
The effect of neoadjuvant chemotherapy for pancreatic cancer was gradually established. However it has been not clarified which regimen of neoadjuvant treatment for pancreatic cancer is the best.
Official title: Neoadjuvant Chemotherapy for Pancreatic Cancer; GS vs. GnP
Key Details
Gender
All
Age Range
18 Years - 85 Years
Study Type
INTERVENTIONAL
Enrollment
500
Start Date
2019-01-01
Completion Date
2030-12-31
Last Updated
2022-03-07
Healthy Volunteers
No
Conditions
Interventions
GS
drip infusion of gemcitabine plus oral administration of S-1 S-1 received S-1 orally twice daily at a dose calculated according to body-surface area (BSA) (\< 1.25 m2, 60 mg/d; ≥ 1.25 to \< 1.5 m2, 80 mg/d; ≥ 1.5 m2, 100 mg/d) on days 1 through 14 of a 21-day cycle gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1 and 8of a 21-day cycle.
GnP
drip infusion of both gemcitabine and nab-paclitacel gemcitabine received gemcitabine intravenously at a dose of 800 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle. nab-paclitaxel received nab-paclitaxel intravenously at a dose of 100 mg/m2 over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
Locations (1)
Takehiro Okabayashi
Kochi, Japan